Success Metrics

Clinical Success Rate

100.0%

Based on 3 completed trials

Completion Rate

100%(3/3)

Active Trials

1(25%)

Results Posted

0%(0 trials)

Phase Distribution

Ph phase_2

75%

Ph not_applicable

25%

Phase Distribution

Early Stage

Mid Stage

Late Stage

Phase Distribution4 total trials

Phase 2Efficacy & side effects

3(75.0%)

N/ANon-phased studies

1(25.0%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

100.0%

3 of 3 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

trials recruiting

Total Trials

all time

Status Distribution

Active(1)

Completed(3)

Detailed Status

Completed3

Recruiting1

Development Timeline

Analytics

Development Status

Total Trials

Active

Success Rate

100.0%

Most Advanced

Phase 2

Trials by Phase

Phase 23 (75.0%)

N/A1 (25.0%)

Trials by Status

recruiting125%

completed375%

Recent Activity

1 active trials

Showing 4 of 4

recruitingnot_applicable

Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke

NCT06649240

completedphase_2

A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

NCT04173793

completedphase_2

A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia

NCT04358432

completedphase_2

A Long-term Study of AK102 in Patients With Hypercholesterolemia

NCT04173403

Clinical Trials (4)

Showing 4 of 4 trials

NCT06649240Not Applicable

Optimal Target Low-density Lipoprotein Cholesterol Level for Small Vessel Occlusion Stroke

Recruiting

NCT04173793Phase 2

A Study of PCSK9 Inhibitor AK102 in Patients With Heterozygous Familial Hypercholesterolemia (HeFH)

Completed

NCT04358432Phase 2

A Study of PCSK9 Inhibitor AK102 in Patients With Hypercholesterolemia

Completed

NCT04173403Phase 2

A Long-term Study of AK102 in Patients With Hypercholesterolemia

Completed

All 4 trials loaded

Drug Details

Intervention Type: DRUG
Total Trials: 4